Literature DB >> 27154871

Effects of Modified Qing'e Pill () on expression of adiponectin, bone morphogenetic protein 2 and coagulation-related factors in patients with nontraumatic osteonecrosis of femoral head.

Cheng-Gang Li1, Lin Shen2, Yan-Ping Yang1, Xiao-Juan Xu1, Bo Shuai1, Chen Ma1.   

Abstract

OBJECTIVES: To observe the regulation of Chinese herbal medicine, Modifified Qing'e Pill (, MQEP), on the expression of adiponectin, bone morphogenetic protein 2 (BMP2), osteoprotegerin (OPG) and other potentially relevant risk factors in patients with nontraumatic osteonecrosis of the femoral head (ONFH).
METHODS: A total of 96 patients with nontraumatic ONFH were unequal randomly divided into treatment group (60 cases) and control group (36 cases). The treatment group were treated with MQEP while the control group were treated with simulated pills. Both groups were given caltrate D. Six months were taken as a treatment course. Patients were followed up every 2 months. The levels of plasma adiponectin, BMP2, OPG, von Willebrand factor (vWF), von Willebrand factor cleaving protease (vWF-cp), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), C-reactive protein (CRP), blood rheology, bone mineral density (BMD) of the femoral head and Harris Hip Score were measured before and after treatment.
RESULTS: After 6 months of treatment, compared with the control group, patients in the treatment group had signifificantly higher adiponectin and BMP2 levels (P<0.01 and P=0.013, respectively), lower vWF, PAI-1 and CRP levels (P=0.019, P<0.01 and P<0.01, respectively), and lower blood rheology parameters. BMD of the femoral neck, triangle area and Harris Hip Score in the treatment group were signifificantly higher than those in the control group. Moreover, plasma adiponectin showed a positive association with BMP2 (r=0.231, P=0.003) and a negative association with PAI-1 (r=-0.159, P<0.05).
CONCLUSION: MQEP may play a protective role against nontraumatic ONFH by increasing the expression of adiponectin, regulating bone metabolism and improving the hypercoagulation state, which may provide an experimental base for its clinical effects.

Entities:  

Keywords:  Chinese herbal medicine; adiponectin; bone morphogenetic protein 2; femoral head; osteonecrosis; plasminogen activator inhibitor 1

Mesh:

Substances:

Year:  2016        PMID: 27154871     DOI: 10.1007/s11655-016-2407-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  29 in total

Review 1.  Clinical use of adiponectin as a marker of metabolic dysregulation.

Authors:  Kieren J Mather; Ronald B Goldberg
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-22       Impact factor: 4.690

2.  Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways.

Authors:  Yusuke Shinoda; Masayuki Yamaguchi; Naoshi Ogata; Toru Akune; Naoto Kubota; Toshimasa Yamauchi; Yasuo Terauchi; Takashi Kadowaki; Yasuhiro Takeuchi; Seiji Fukumoto; Toshiyuki Ikeda; Kazuto Hoshi; Ung-il Chung; Kozo Nakamura; Hiroshi Kawaguchi
Journal:  J Cell Biochem       Date:  2006-09-01       Impact factor: 4.429

3.  Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast.

Authors:  Kazuya Oshima; Akihide Nampei; Morihiro Matsuda; Masanori Iwaki; Atsunori Fukuhara; Jun Hashimoto; Hideki Yoshikawa; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2005-06-03       Impact factor: 3.575

Review 4.  Nontraumatic osteonecrosis of the femoral head: ten years later.

Authors:  Michael A Mont; Lynne C Jones; David S Hungerford
Journal:  J Bone Joint Surg Am       Date:  2006-05       Impact factor: 5.284

5.  Adiponectin and its receptors are expressed in bone-forming cells.

Authors:  Heidi S Berner; Staale P Lyngstadaas; Axel Spahr; Marta Monjo; Liv Thommesen; Christian A Drevon; Unni Syversen; Janne E Reseland
Journal:  Bone       Date:  2004-10       Impact factor: 4.398

6.  Influence of factors regulating bone formation and remodeling on bone quality in osteonecrosis of the femoral head.

Authors:  Markus Tingart; Johannes Beckmann; Alfred Opolka; Maiko Matsuura; Oliver Wiech; Joachim Grifka; Susanne Grässel
Journal:  Calcif Tissue Int       Date:  2008-03-05       Impact factor: 4.333

7.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11

8.  Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells.

Authors:  Hyun Woo Lee; Sang Yun Kim; A Young Kim; Eun Jig Lee; Je-Yong Choi; Jae Bum Kim
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

9.  Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats.

Authors:  Yoshihiro Nozaki; Kenji Kumagai; Noriaki Miyata; Masami Niwa
Journal:  Acta Orthop       Date:  2012-02       Impact factor: 3.717

10.  Systemic antithrombotic effects of ADAMTS13.

Authors:  Anil K Chauhan; David G Motto; Colin B Lamb; Wolfgang Bergmeier; Michael Dockal; Barbara Plaimauer; Friedrich Scheiflinger; David Ginsburg; Denisa D Wagner
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

View more
  9 in total

Review 1.  Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis.

Authors:  Junjie Lu; Desheng Hu; Chen Ma; Bo Shuai
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

2.  Increased serum protein levels by Yuanshi Shengmai Chenggu Tablet in treatment of avascular osteonecrosis of the femoral head.

Authors:  Jianchun Zeng; Peng Deng; Jie Li; Wenjun Feng; Jinlun Chen; Yirong Zeng
Journal:  Mol Med Rep       Date:  2017-11-20       Impact factor: 2.952

3.  Association of Traditional Chinese Medicine Therapy with Risk of Total Hip Replacement in Patients with Nontraumatic Osteonecrosis of the Femoral Head: A Population-Based Cohort Study.

Authors:  Yu-An Yeh; Jen-Huai Chiang; Mei-Yao Wu; Chun-Hao Tsai; Horng-Chaung Hsu; Hsin-Cheng Hsu; Tsung-Li Lin
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-24       Impact factor: 2.629

4.  Qing`e Pill Inhibits Osteoblast Ferroptosis via ATM Serine/Threonine Kinase (ATM) and the PI3K/AKT Pathway in Primary Osteoporosis.

Authors:  Jian Hao; Jiaxin Bei; Zhenhan Li; Mingyuan Han; Boyuan Ma; Pengyi Ma; Xianhu Zhou
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

5.  The analysis of Modified Qing' E Formula on the differential expression of exosomal miRNAs in the femoral head bone tissue of mice with steroid-induced ischemic necrosis of femoral head.

Authors:  Wei Zhu; Faxue Zhang; Junjie Lu; Chen Ma; Lin Shen; Desheng Hu; Xiaojuan Xu; Bo Shuai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-10       Impact factor: 6.055

6.  Modified Qing' e Pills exerts anti-osteoporosis effects and prevents bone loss by enhancing type H blood vessel formation.

Authors:  Junjie Lu; Desheng Hu; Chen Ma; Xiaojuan Xu; Lin Shen; Jianhui Rong; Jia Zhao; Bo Shuai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-06       Impact factor: 6.055

7.  Tongue Manifestation in Patients with Osteonecrosis of the Femoral Head: A Cross-sectional Study.

Authors:  Yan Jia; Jigao Sun; Zhaoxu Jia; Zhipeng Xue; Rongtian Wang; Haijun He; Weiheng Chen
Journal:  Orthop Surg       Date:  2022-07-27       Impact factor: 2.279

8.  Screening of Serum Protein Markers for Avascular Osteonecrosis of Femoral Head Differentially Expressed after Treatment with Yuanshi Shengmai Chenggu Tablets.

Authors:  Peng Deng; Jianchun Zeng; Jie Li; Wenjun Feng; Jinlun Chen; Yirong Zeng
Journal:  Biomed Res Int       Date:  2018-03-20       Impact factor: 3.411

9.  Huo Xue Tong Luo capsule, a vasoactive herbal formula prevents progression of asymptomatic osteonecrosis of femoral head: A prospective study.

Authors:  Qiu-Shi Wei; Guo-Ju Hong; Ying-Jia Yuan; Zhen-Qiu Chen; Qing-Wen Zhang; Wei He
Journal:  J Orthop Translat       Date:  2018-12-21       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.